OpenAI's GPT-Rosalind: How the Life Sciences Model Is Transforming Research

On April 16, 2026, OpenAI unveiled GPT-Rosalind, its first reasoning model specifically designed for life sciences research. Here’s a breakdown of the announcement, its claimed capabilities, access requirements—and the room it leaves for European alternatives like Charlie.

Emerit Science

Emerit Science Team

April 2026 Updated November 2, 2026
OpenAI's GPT-Rosalind: A Life Sciences Model vs. Charlie

On April 16, 2026, OpenAI announced GPT-Rosalind, the first model in a new series dedicated to the life sciences. Named in honor of Rosalind Franklin—whose work helped elucidate the structure of DNA—it aims to shorten the early stages of drug discovery, where researchers juggle literature reviews, specialized databases, experimental data, and constantly evolving hypotheses.

The announcement confirms a view we at Emerit Science have held from the start: AI agents specialized for scientific research are a distinct category from general-purpose assistants. But it also raises a practical question for European labs—both academic and private: what should they do with a cutting-edge model launched with limited access, reserved for U.S. enterprise customers, and hosted on OpenAI’s infrastructure?

What is GPT-Rosalind?

GPT-Rosalind is a reasoning model from the GPT family, optimized for scientific workflows. It combines a deep understanding of chemistry, protein engineering, and genomics with an enhanced ability to utilize scientific tools and databases within multi-step processes.

Tasks for which OpenAI positions it:

  • Literature Review and Summary of the Evidence
  • Interpretation of sequence-function relationships (DNA, RNA, proteins)
  • Experimental design and data analysis
  • Research on molecules, biological pathways, and disease-related biology
  • Multi-step workflow orchestration via the Codex Life Sciences plugin (50+ tools and public databases)

In addition to the model, OpenAI is releasing a Codex Life Sciences plugin on GitHub (free of charge). It provides an orchestration layer for over 50 public resources (human genetics, functional genomics, protein structure, biochemistry, clinical data, and public datasets). This plugin also works with the main GPT-5+ models for users without access to GPT-Rosalind.

Reported performance: results to take seriously

OpenAI has published several benchmarks in which GPT-Rosalind ranks first among the models tested on scientific tasks:

  • BixBench (real-world bioinformatics tasks): a score of 0.751, compared to 0.732 for GPT-5.4 and 0.728 for GPT-5. The best result published to date.
  • LABBench2 (literature search, database access, sequence manipulation, protocol design): outperformed GPT-5.4 on 6 out of 11 tasks, with the largest improvement observed on CloningQA (design of DNA and enzymatic reagents for molecular cloning protocols).
  • Dyno Therapeutics evaluation (RNA sequence-function prediction and generation): top submissions outperformed human experts in prediction by more than 95 percentiles, and ranked around the 84th percentile in generation.

These figures are compelling. They show that a model specialized in biology outperforms a general-purpose model of the same generation on specific scientific tasks. For teams engaged in large-scale drug discovery, the potential productivity gains are significant.

Access requirements: a model reserved for a select group

This is where the announcement requires careful reading. GPT-Rosalind is being launched through a “secure access program,” with several cumulative conditions:

  • Initially available to eligible enterprise customers in the United States — no European availability has been announced as of the date of this announcement.
  • OpenAI's safety qualification and assessment: legitimate scientific use, governance, compliance, and abuse prevention.
  • Access via ChatGPT, Codex, and the API, subject to certain conditions; the model is not available on a self-service basis like GPT-5.
  • Key partners: Amgen, Moderna, Novo Nordisk, Thermo Fisher Scientific, the Allen Institute, NVIDIA, Benchling, Oracle Health, UCSF, and Los Alamos National Laboratory. And consulting partners for integration: McKinsey, BCG, and Bain.

This access strategy—which is justifiable from a biosafety perspective—also shapes the product’s positioning: GPT-Rosalind is aimed at large U.S. pharmaceutical and biotech companies capable of engaging a consulting firm to implement the model. It excludes the majority of European academic laboratories, biotech SMEs, and public research teams.

What this means for European laboratories

For a research unit director, an R&D manager in biotech or a head of a translational oncology team in France, several questions arise:

  • When will it be available in Europe? No timeline has been announced. Based on OpenAI’s experience with its Enterprise products, it could take anywhere from several months to several quarters before a controlled rollout outside the U.S.
  • What does data sovereignty entail? The platform is hosted on OpenAI’s infrastructure (Microsoft Azure in the United States). The U.S. Cloud Act applies. For sensitive research data—unpublished results, patentable hypotheses, patient data—this is a major sticking point for many European organizations.
  • What are the operational costs? It’s free during the preview period, but will eventually be subject to a fee. The need to hire a consulting firm for integration increases the total cost.
  • What strategic dependency? Adopting GPT-Rosalind means making part of your R&D pipeline rely on a single non-European provider, in a sector where technological sovereignty is becoming an industrial issue.

None of these questions is a deal-breaker—but each one requires an explicit answer before you commit critical data and workflows.

Charlie: a sovereign alternative, available today

Charlie, Emerit Science's scientific AI agent, targets the same workflows as GPT-Rosalind—literature search, data analysis, experimental design, and biological reasoning—but with a different approach in three key areas:

  • French sovereignty: core of the system hosted and operated in France, models run in the European Union, no training on your data, GDPR-compliant. A 100% France configuration is available for organizations that request it. ProConnect authentication for government staff.
  • European sources included: Charlie natively indexes HAL (French-language scientific output), bioRxiv, PubMed and PMC (full text, queried alone for now), with Internet as an option. Clickable citations that open the source record, and deduplication across sources.
  • Accessible to laboratories of all sizes: free account, Premium and Team plans, Organization quote. No eligibility program, no mandatory consulting firm to get started.

Charlie does not claim to beat GPT-Rosalind on pure bioinformatics benchmarks. Our strength lies elsewhere: a unified workflow — technology and market watch, data analysis, experimental approach, integrations (ProConnect, Index API, and eLabFTW coming soon) — available to teams that need to work today, within a framework compliant with European regulation.

Comparison Chart

Criterion GPT-Rosalind Charlie (Emerit Science)
Field Life Sciences (drug discovery, biology, translational medicine) Scientific research in the broadest sense (biomedical, biotechnology, academic research)
Availability Research preview, eligible U.S. enterprises Public availability worldwide (12 languages)
Accommodation OpenAI / Microsoft Azure (U.S., Cloud Act) Sovereign French host (core of the system in France, models in the EU)
Access Secure access program; qualification required Self-service, free / Premium / Team / Organization
Scientific sources Over 50 public databases via the Codex plugin PubMed, bioRxiv, HAL, PMC, Internet as an option
French-language sources (HAL) Undocumented Yes, native
GDPR / AI Act Compliance To be evaluated on a case-by-case basis GDPR-compliant
Target audience Big Pharma and U.S. biotech companies (Amgen, Moderna, etc.) Research units, biotech SMEs, PhD students, university hospitals, European R&D teams
“GPT-Rosalind proves one thing: scientific research deserves dedicated models, not repurposed general-purpose assistants. That’s exactly the conviction that led us to build Charlie. However, a model reserved for major U.S. players doesn’t solve the problem for the majority of European laboratories—and it is this majority that Charlie serves on a daily basis.” — The Emerit Science Team

Who should choose what?

GPT-Rosalind is a good fit if you:

  • - Are you a U.S. pharmaceutical or biotech company?
  • - Have a highly specialized drug discovery pipeline
  • - Make the necessary arrangements to take the entrance exam
  • - Accept OpenAI/Microsoft Azure hosting
  • - Do you have the budget to hire a consulting firm for the integration?

Charlie is relevant if you:

  • - Work in Europe (joint research units, university hospitals, biotech companies, universities)
  • - Need a solution that's available today
  • - Require GDPR compliance and hosting in France
  • - Would you like to access French-language sources (HAL)?
  • - Opt for a self-service startup without a consulting firm
  • - Look for a unified workflow: monitoring, analysis, traceability, and integrations

The two tools are not in direct competition: GPT-Rosalind targets a specific segment (U.S. Big Pharma), while Charlie serves the European research ecosystem in all its diversity—from PhD students to R&D executives.

Conclusion: Confirmation that a sovereign scientific AI was necessary

GPT-Rosalind marks a significant milestone: OpenAI has officially validated the idea that an AI model tailored to the life sciences offers a measurable advantage over general-purpose models. This is excellent news for the broader scientific community.

But the announcement also highlights a structural risk for Europe: allowing the next generation of scientific tools to be built exclusively on the infrastructure of a few American companies, with access conditions that exclude mid-sized laboratories and public entities. This is precisely the raison d'être of Charlie: to enable European teams to benefit from advances in scientific AI without sacrificing their data sovereignty or strategic independence.

The question isn’t “GPT-Rosalind or Charlie?” but “What does my lab need right now to move forward, within a framework I can control?” For the vast majority of the teams we support, the answer is clear.

Try Charlie for free

Charlie is available today for European laboratories and researchers. Core of the system hosted in France, PubMed / bioRxiv / HAL / PMC sources included, GDPR-compliant.

Try Charlie for free

Share this article: